Free Trial
→ Collect $7k per month from Tesla’s SECRET dividend (From Investors Alley) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • Five stocks to consider instead of Denali Therapeutics.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should You Invest $1,000 in Denali Therapeutics Right Now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
4.4743 of 5 stars		$14.29+2.7%N/A-5.18Buy$33.71
Ultragenyx Pharmaceutical (RARE)
3.9896 of 5 stars		$37.35+3.2%N/A-5.89Moderate Buy$90.93
Sarepta Therapeutics (SRPT)
4.815 of 5 stars		$39.99+5.4%N/A31.99Moderate Buy$122.61
Pfizer (PFE)
4.9524 of 5 stars		$23.51+2.2%7.32%16.67Moderate Buy$29.17
Exelixis (EXEL)
4.2667 of 5 stars		$44.36-0.7%N/A25.06Hold$38.94
Moderna (MRNA)
4.5319 of 5 stars		$27.99+6.1%N/A-3.02Hold$53.95
United Therapeutics (UTHR)
4.9819 of 5 stars		$309.57+1.4%N/A13.60Moderate Buy$392.00
Biogen (BIIB)
4.9177 of 5 stars		$130.55+0.9%N/A11.67Hold$191.30
Sanofi (SNY)
4.0924 of 5 stars		$52.89+1.2%3.03%21.24Buy$63.33
Eli Lilly and Company (LLY)
4.9796 of 5 stars		$745.72-1.2%0.80%63.68Moderate Buy$1,011.37
Compare These Stocks  Add These Stocks to My Watchlist 

Featured Articles and Offers

Recent Videos

Magnificent 7 Stocks Shift Toward Stability and Selective Growth
4 Biotech Stocks on the Verge of Massive Breakthroughs
New AI Deals Just Sent These 4 Infrastructure Stocks Soaring

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines